Gujarat Inject (Kerala) posts 7x revenue jump in Q4, flips to profit
Q4 revenue surged to ₹30.7 cr from ₹4.2 cr a year earlier; net profit of ₹1.64 cr reverses losses. Capital work-in-progress of ₹20.8 cr signals a major expansion phase.
— 1 earlier story on Gujarat Inject (Kerala) Ltd. →What's new
- Q4 revenue surged to ₹30.7 cr from ₹1.6 cr in preceding quarter and ₹4.2 cr a year ago.
- Net profit of ₹1.64 cr in Q4, reversing recent losses.
- Balance sheet shows ₹20.8 cr in capital work-in-progress, hinting at major expansion.
Why it matters
For a nano-cap, this is a material inflection point. The scale of the turnaround suggests either a large new contract or a fundamental business shift. The CWIP of ₹20.8 cr relative to full-year revenue of ₹36.3 cr means the company is investing heavily for future capacity—capital expenditure is outpacing current operations.
What we're watching
- Whether the revenue spike is sustainable or a one-off.
- Progress on the capital work-in-progress converting to revenue-generating assets.
- FY27 guidance or any management commentary; cash flow and debt levels given the expansion.
The full read
Gujarat Inject (Kerala) moved from near-zero revenue to ₹30.7 cr in a single quarter, propelling full-year revenue to ₹36.3 cr—almost double the prior year. Profitability returned with a net profit of ₹1.64 cr in Q4, reversing recent losses. More tellingly, the balance sheet now carries ₹20.8 cr in capital work-in-progress, a figure that represents more than half of the year's total revenue. This suggests the company is not just enjoying a one-off bump but actively expanding capacity—a rare move for a nano-cap. The open question is sustainability: can the company maintain this run rate, and how will it fund the expansion? The next quarterly numbers will be the real test.